Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Open access

Abstract

Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdu385

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 143 references

Research works printed but not linked: 2

  1. Piccart-Gebhart, 2014, J Clin Oncol, 32
  2. Wildiers, 2013, T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice, Presented at the European Cancer Congress

Cited by

See all 540

Metadata

Authors
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
Affiliations
  • Centro Champalimaud (PT)
  • European School of Oncology (CH)
  • Memorial Sloan Kettering Cancer Center (US)
  • Gdańsk Medical University (PL)
  • Clinique de Genolier (CH)
  • Institut Gustave Roussy (FR)
  • Pontifícia Universidade Católica do Rio Grande do Sul (BR)
  • Karolinska University Hospital (SE)
  • Fondazione Sandro Pitigliani (IT)
  • Duke University (US)
  • Champalimaud Foundation (PT)
  • Brighton and Sussex Medical School (GB)
  • Europa Donna (IT)
  • Peter MacCallum Cancer Centre (AU)
  • BC Cancer Agency (CA)
  • The University of Texas MD Anderson Cancer Center (US)
  • Université Pierre-et-Marie-Curie (FR)
  • European Institute of Oncology (IT)
  • Ludwig-Maximilians-Universität München (DE)
  • The University of Sydney (AU)
  • Sheba Medical Center (IL)
  • Dana-Farber Cancer Institute (US)
  • University of Michigan (US)
  • Europa Donna (GE)
  • Istituto Oncologico della Svizzera Italiana (CH)
  • Centre Jean Perrin (FR)
  • Institut Jules Bordet (BE)
  • University of California, San Francisco (US)
  • Indiana University (US)
  • Martin Luther University Halle-Wittenberg (DE)
  • Cardiff and Vale University Health Board (GB)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Cardoso, F.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2014-10
Volume
25
Issue
10
Pages
1871-1888
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2127287298
Cited by
540
References
143
Citations by year
2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
FWCI
33.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
  • OAR@UM (University of Malta) (submittedVersion, other-oa)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
MeSH terms
Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). https://app.cochat.ai/papers/10.1093/annonc/mdu385
The paper
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., . . . Winer, E. (2014). ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Annals of Oncology. https://doi.org/10.1093/annonc/mdu385

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.